Seattle Genetics Inc. has axed its $2 billion licensing deal with Immunomedics Inc.
Bothell-based Seattle Genetics signed the deal in February to purchase worldwide licensing rights to a cancer drug known as IMMU-132 from Immunomedics Inc.
Seattle Genetics is the largest biotechnology company in the Puget Sound region, with more than 900 employees and a current market capitalization of $8.3 billion.
"Seattle Genetics would have been a great partner for IMMU-132, as it effectively utilizes our…
Seattle Genetics Inc. has axed its $2 billion licensing deal with Immunomedics Inc.
Bothell-based Seattle Genetics signed the deal in February to purchase worldwide licensing rights to a cancer drug known as IMMU-132 from Immunomedics Inc.
Seattle Genetics is the largest biotechnology company in the Puget Sound region, with more than 900 employees and a current market capitalization of $8.3 billion.
"Seattle Genetics would have been a great partner for IMMU-132, as it effectively utilizes our…